{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026404","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.706509+00:00","generated_at":"2026-06-18T22:09:50.663617+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theravance Biopharma increases buyback to $325M, announces formal strategic review","bullets":["Capital Return Program increased to $325M; $170M remaining expected by end of 2023; $27M repurchased YTD 2023.","Q4 2022 YUPELRI sales $19.5M (up 27% YoY); TRELEGY global net sales $537M (up 13% YoY).","Non-GAAP profit expected in 2H 2023; 2023 R&D guidance $35-45M, SG&A $45-55M.","Appointed Susannah Gray (ex-Royalty Pharma CFO) to Board; Board declassification proposal submitted.","Announced formal strategic review; responding to Irenic Capital's activist claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026404","json":"https://secwatch.observer/filing/0001104659-23-026404.json","markdown":"https://secwatch.observer/filing/0001104659-23-026404.md","text":"https://secwatch.observer/filing/0001104659-23-026404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923026404/0001104659-23-026404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923026404/tm238017d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:09:50.663617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}